Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES)

International Journal of Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles